Swedish Orphan Biovitrum AB (publ) Cash Flow Conversion Efficiency

Latest as of March 2026: 0.028x

Swedish Orphan Biovitrum AB (publ) cash flow conversion efficiency. Based on the latest financial reports, Swedish Orphan Biovitrum AB (publ) (SOBI) has a cash flow conversion efficiency ratio of 0.028x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr1.13 Billion ≈ $121.18 Million USD) by net assets (Skr40.38 Billion ≈ $4.35 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Swedish Orphan Biovitrum AB (publ) (2002–2025)

Cash flow conversion efficiency of Swedish Orphan Biovitrum AB (publ) from 2002 to 2025. This chart illustrates how Swedish Orphan Biovitrum AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View SOBI share price today for real-time trading data and today's change.

Swedish Orphan Biovitrum AB (publ) Cash Flow Conversion Ratio Explained

Swedish Orphan Biovitrum AB (publ) cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Swedish Orphan Biovitrum AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Swedish Orphan Biovitrum AB (publ) ranked by their cash flow conversion efficiency. Also see market value of Swedish Orphan Biovitrum AB (publ) for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
General Mills Inc NYSE:GIS	0.075x
TECHTRONIC INDS ADR/5 F:TIB	N/A
Bouygues SA PA:EN	0.113x
Illumina Inc NASDAQ:ILMN	0.104x
SGS SA SW:SGSN	1.357x
INTERCONT HOTELS F:IC1B	N/A
Broadridge Financial Solutions Inc NYSE:BR	0.107x
BANCO BRANDESCO SP.ADR 1 F:BREA	-0.111x

Annual Cash Flow Conversion Efficiency for Swedish Orphan Biovitrum AB (publ) (2002–2025)

The table below shows the annual cash flow conversion efficiency of Swedish Orphan Biovitrum AB (publ) from 2002 to 2025. Review cash generation quality of Swedish Orphan Biovitrum AB (publ) to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr37.72 Billion ≈ $4.06 Billion	Skr8.56 Billion ≈ $921.62 Million	0.227x	+23.82%
2024-12-31	Skr40.30 Billion ≈ $4.34 Billion	Skr7.39 Billion ≈ $795.07 Million	0.183x	+38.91%
2023-12-31	Skr33.87 Billion ≈ $3.64 Billion	Skr4.47 Billion ≈ $481.04 Million	0.132x	-24.95%
2022-12-31	Skr26.52 Billion ≈ $2.85 Billion	Skr4.67 Billion ≈ $502.03 Million	0.176x	-25.40%
2021-12-31	Skr23.20 Billion ≈ $2.50 Billion	Skr5.47 Billion ≈ $588.66 Million	0.236x	-8.64%
2020-12-31	Skr20.21 Billion ≈ $2.17 Billion	Skr5.21 Billion ≈ $561.11 Million	0.258x	+20.22%
2019-12-31	Skr16.93 Billion ≈ $1.82 Billion	Skr3.63 Billion ≈ $391.08 Million	0.215x	-7.17%
2018-12-31	Skr9.04 Billion ≈ $972.86 Million	Skr2.09 Billion ≈ $224.95 Million	0.231x	+16.23%
2017-12-31	Skr6.70 Billion ≈ $721.08 Million	Skr1.33 Billion ≈ $143.45 Million	0.199x	+210.66%
2016-12-31	Skr5.35 Billion ≈ $576.21 Million	Skr342.86 Million ≈ $36.90 Million	0.064x	-40.80%
2015-12-31	Skr4.69 Billion ≈ $504.65 Million	Skr507.20 Million ≈ $54.58 Million	0.108x	+109.27%
2014-12-31	Skr4.52 Billion ≈ $486.73 Million	Skr233.77 Million ≈ $25.16 Million	0.052x	+32.97%
2013-12-31	Skr4.77 Billion ≈ $513.25 Million	Skr185.39 Million ≈ $19.95 Million	0.039x	-53.62%
2012-12-31	Skr4.84 Billion ≈ $520.65 Million	Skr405.47 Million ≈ $43.64 Million	0.084x	+304.14%
2011-12-31	Skr4.96 Billion ≈ $534.14 Million	Skr102.93 Million ≈ $11.08 Million	0.021x	+141.86%
2010-12-31	Skr4.34 Billion ≈ $467.31 Million	Skr-215.10 Million ≈ $-23.15 Million	-0.050x	-213.80%
2009-12-31	Skr1.35 Billion ≈ $145.58 Million	Skr58.88 Million ≈ $6.34 Million	0.044x	+111.04%
2008-12-31	Skr1.28 Billion ≈ $138.28 Million	Skr-506.49 Million ≈ $-54.51 Million	-0.394x	-2156.87%
2007-12-31	Skr1.45 Billion ≈ $156.34 Million	Skr-25.37 Million ≈ $-2.73 Million	-0.017x	+72.56%
2006-12-31	Skr1.38 Billion ≈ $148.70 Million	Skr-87.96 Million ≈ $-9.47 Million	-0.064x	-66.41%
2005-12-31	Skr1.71 Billion ≈ $183.77 Million	Skr-65.32 Million ≈ $-7.03 Million	-0.038x	+62.02%
2004-12-31	Skr2.08 Billion ≈ $223.37 Million	Skr-209.03 Million ≈ $-22.50 Million	-0.101x	-127.94%
2003-12-31	Skr2.10 Billion ≈ $225.57 Million	Skr755.60 Million ≈ $81.31 Million	0.360x	+6368.45%
2002-12-31	Skr1.73 Billion ≈ $185.73 Million	Skr9.62 Million ≈ $1.04 Million	0.006x	--

About Swedish Orphan Biovitrum AB (publ)

ST:SOBI Sweden Drug Manufacturers - Specialty & Generic

Market Cap

$18.24 Billion

Skr169.53 Billion SEK

Market Cap Rank

#1352 Global

#21 in Sweden

Share Price

Skr490.20

Change (1 day)

+0.45%

52-Week Range

Skr317.00 - Skr490.20

All Time High

Skr490.20